Fig. 5: ERBB2 expression in SCLC in patients. | Nature Communications

Fig. 5: ERBB2 expression in SCLC in patients.

From: ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer

Fig. 5

a Schematic of FFPE samples of unmatched lung and liver samples from SCLC patients (n = 35) stained for ERBB2 and MHC-I in IHC. Created in BioRender. Meder, L. (2025) https://BioRender.com/x5oxh7c. b Proportional distribution of ERBB2-negative and ERBB2-focally positive patient samples. c ERBB2 and MHC-I IHC staining of one representative patient case. Images were taken at 20× magnification. Scale bars, 100 µm and 25 µm, respectively. d Correlation of ERBB2 and MHC-I expression based on QuPath-guided IHC analysis of representative ROIs from four patients. Clinicopathologic characteristics are listed in the Supplementary Data 10. A Pearson correlation analysis was performed, and a linear regression line was added to the graph. e Proportional distribution of ERBB2 low and ERBB2 high patient samples (low ERBB2 < 6%, high ERBB2 > 6%) in scRNA-seq data10. f Dot plot of scRNA-seq data10 comparing primary tumors (n = 9) to metastatic sites, including liver, pleural effusion, adrenal gland and axillary lymph nodes (n = 6). *p <  0.05. Source data are provided as a Source Data file.

Back to article page